AbCellera Biologics (ABCL) Net Income towards Common Stockholders: 2019-2024
Historic Net Income towards Common Stockholders for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$162.9 million.
- AbCellera Biologics' Net Income towards Common Stockholders fell 57.73% to -$47.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.4 million, marking a year-over-year decrease of 192.35%. This contributed to the annual value of -$162.9 million for FY2024, which is 11.24% down from last year.
- Per AbCellera Biologics' latest filing, its Net Income towards Common Stockholders stood at -$162.9 million for FY2024, which was down 11.24% from -$146.4 million recorded in FY2023.
- Over the past 5 years, AbCellera Biologics' Net Income towards Common Stockholders peaked at $158.5 million during FY2022, and registered a low of -$162.9 million during FY2024.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$146.4 million (2023), whereas its average is -$50.2 million.
- In the last 5 years, AbCellera Biologics' Net Income towards Common Stockholders skyrocketed by 5,478.47% in 2020 and then tumbled by 192.35% in 2023.
- Over the past 5 years, AbCellera Biologics' Net Income towards Common Stockholders (Yearly) stood at $118.9 million in 2020, then grew by 29.05% to $153.5 million in 2021, then grew by 3.29% to $158.5 million in 2022, then crashed by 192.35% to -$146.4 million in 2023, then decreased by 11.24% to -$162.9 million in 2024.